

Oncology Agents: Radiopharmaceuticals (Lutathera)

WA.PHAR.88 Oncology Agents: Radiopharmaceuticals (Lutathera)

Effective Date: July 1, 2019

Background:

Lutetium Lu 177 dotatate (Lutathera®) is a radiolabeled somatostatin analog managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
A9513	LUTETIUM LU 177 DOTATATE THERAPEUTIC 1 MCI

History

Date	Action and Summary of Changes
06/24/2020	New Policy Created